Myriad Genetics (MYGN) says the U.S. Supreme Court has agreed to hear the Association for...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN) says the U.S. Supreme Court has agreed to hear the Association for Molecular Pathology's case against MYGN. The Supreme Court will review an earlier decision by the U.S. Court of Appeals for the Federal Circuit that ruled in favor of the drug developer, declaring the company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible.